DUARTE, Calif., Dec. 7 /PRNewswire/ -- Alexandra M. Levine, M.D., has
been named chief medical officer (CMO) of City of Hope. An internationally
known expert in lymphoma, Hodgkin's disease and AIDS-related malignancies,
Levine will be the organization's chief clinician and will oversee all
clinical and hospital care programs at City of Hope. Levine was most
recently Distinguished Professor of Medicine, chair of the Division of
Hematology at the Keck School of Medicine of the University of Southern
California (USC), and medical director of USC/Norris Cancer Hospital.
As City of Hope's CMO, Levine will develop and implement the
institution's clinical strategy and program development. She will serve as
the primary liaison with the City of Hope Medical Group and its physician
members to promote collaboration across disciplines and ensure effective
staff recruitment and retention. Levine will co-lead programs aimed at
continually improving the standard of care at City of Hope, including
quality of service, patient safety, clinical research, clinical information
management and professional education. As chief clinician she will serve as
a role model and facilitator for all clinical staff.
"We are thrilled to have Alexandra Levine join City of Hope. She brings
both her vast scientific expertise in hematology and HIV, and also her
limitless compassion for patients facing cancer," said Michael A. Friedman,
M.D., president and chief executive officer, City of Hope. "Dr. Levine is a
noted advocate of bringing more humanism into medicine and can address
quality patient care from all angles, managing the needs of patients while
also providing guidance for the physicians who treat them."
Levine is a distinguished professor at Keck School of Medicine, and
holds the Ronald H. Bloom Family Chair in Lymphoma. Her research interests
include lymphoma, Hodgkin's disease, and treating and preventing HIV/AIDS
among women. She worked for eight years with Jonas Salk, M.D., on the
development and testing of an AIDS vaccine. Levine has served as principal
investigator or co- investigator on more than 20 major research grants,
most funded by the National Institutes of Health.
Levine's scientific and clinical contributions have received national
and international recognition. In 1995, President Clinton appointed her to
the Presidential Advisory Council on HIV/AIDS. She also chaired the
council's research committee. Levine has served as a member of the board of
councilors of the National Cancer Institute and is currently a member of
the Oncologic Drug Advisory Board of the Food and Drug Administration. In
addition, she served as HIV/AIDS consultant to the health departments of
Chile, Russia, India and China.
"I am delighted and honored to be given the opportunity to work with
the City of Hope family. This institution has always distinguished itself
by its commitment to quality in terms of patient care and research, and by
the kindness and caring that has always been integral to its mission," said
Levine. "City of Hope is now poised to move to the next levels of expertise
and national leadership, and I am most thankful to be given the chance to
participate in this very exciting future."
Levine is a member of the American Society of Hematology, the American
Society of Clinical Oncology, the American College of Physicians and the
International AIDS Society. She has published more than 300 articles and
book chapters in noted medical journals such as the New England Journal of
Medicine, Blood and the Journal of AIDS. In 1997, she received the Lymphoma
Research Foundation of America's Evelyn Hoffman Memorial Award in
recognition for her achievements in lymphoma research and patient care.
Levine received her medical degree from USC in 1971 and completed
fellowships at Emory University and Los Angeles County+USC Medical Center.
About City of Hope
City of Hope is a leading research and treatment center for cancer,
diabetes and other life-threatening diseases. Designated as a Comprehensive
Cancer Center, the highest honor bestowed by the National Cancer Institute,
and a founding member of the National Comprehensive Cancer Network, City of
Hope's research and treatment protocols impact care throughout the nation.
Founded in 1913, City of Hope is a pioneer in the fields of bone marrow
transplantation and genetics and shares its scientific knowledge with
medical centers locally and globally, helping patients battling serious
diseases. For more information, visit www.cityofhope.org.
SOURCE City of Hope